Gan & Lee Pharmaceuticals

Gan & Lee's Monthly Bofanglutide Holds Weight in Phase III Trial

Beijing – November 04, 2026 -- Gan & Lee Pharmaceuticals (Stock Code: 603087.SH) reported that once-monthly bofanglutide met the primary endpoint of its Phase IIIb GRADUAL-3 study, holding body weight near baseline over 24 weeks while the placebo group changed by 8.52%.

Both monthly dose groups beat placebo at P0.0001

Mean body-weight changes from baseline were 0.41% in the 24 mg once-monthly group and -0.12% in the 48 mg group, against 8.52% for placebo. Both comparisons reached P0.0001. The primary endpoint was the percentage change in body weight from baseline after 24 weeks.

Gan & Lee Licenses Obesity Drug to Menarini in Deal Worth Up to €726M

Beijing/Florence – September 09, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive licensing agreement with Italy's The Menarini Group for its GLP-1 receptor agonist bofanglutide, a deal worth up to €726 million excluding royalties.

Gan & Lee secures €62 million upfront payment plus milestone potential of €664 million

Under the terms, Gan & Lee will receive a €62 million upfront payment, up to €664 million in milestone payments, and double-digit royalties on net sales across the licensed territory. Menarini will handle regulatory filings and commercialization in 39 countries, covering all 27 European Union member states, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan nations.

Gan & Lee Licenses Obesity Drug Bofanglutida to Menarini for €726M

Beijing/Florence – September 09, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive license agreement with Italy's Menarini Group worth up to €726 million, excluding royalties, to develop and commercialize the obesity drug bofanglutida across 39 European markets.

Gan & Lee secures €62 million upfront with milestones reaching €664 million

Under the deal, Gan & Lee will receive an initial payment of €62 million, milestone payments totaling up to €664 million, and double-digit royalties on net sales within the licensed territory. Menarini will handle regulatory filings and commercialization in the 27 European Union member states, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan countries.

Gan & Lee, Menarini Ink EUR726M Deal for GLP-1 Obesity Drug

Beijing – September 08, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive license agreement with Italy's Menarini Group worth up to EUR 726 million, excluding royalties, to register and commercialize its GLP-1 receptor agonist bofanglutide for obesity and overweight treatment across 39 countries.

Deal structure delivers EUR 62 million upfront with EUR 664 million in milestones

Gan & Lee will receive an upfront payment of EUR 62 million, milestone payments totaling up to EUR 664 million, and double-digit royalties on net sales in the licensed territory. Menarini takes responsibility for regulatory submissions and commercialization across the 27 EU Member States plus the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan countries.